HUP0004317A2 - 5-HT1F agonisták - Google Patents
5-HT1F agonistákInfo
- Publication number
- HUP0004317A2 HUP0004317A2 HU0004317A HUP0004317A HUP0004317A2 HU P0004317 A2 HUP0004317 A2 HU P0004317A2 HU 0004317 A HU0004317 A HU 0004317A HU P0004317 A HUP0004317 A HU P0004317A HU P0004317 A2 HUP0004317 A2 HU P0004317A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- carbon
- halogen atom
- alkyl
- ht1f
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 102100036311 5-hydroxytryptamine receptor 1F Human genes 0.000 abstract 2
- 101710138086 5-hydroxytryptamine receptor 1F Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005466 alkylenyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Battery Electrode And Active Subsutance (AREA)
Abstract
A találmány tárgyát az (I) általános képletű 5-HTlF agonisták képezik,amelyekben A-B, X és R jelentését az alábbiakban definiálják. Atalálmány tárgyát képezik továbbá azok a gyógyászati készítmények,amikben a találmány szerinti vegyületeket alkalmazzák, valamint azokaz eljárások, amikkel az 5-HT1F aktiváláshoz kapcsolódó állapotokatlehet ezekkel a vegyületekkel vagy készítményekkel kezelni. (I)általános képletű vegyület, amiben A-B jelentése -CH=CH- vagy -CH-CH2csoport; R jelentése hidrogénatom, 1-6 szénatomszámos alkil-, benzil-vagy feniletil-csoport; X jelentése halogénatom, 1-4-szénatomszámosalkoxi-, -NHR1-, -C(O)OR2- vagy -C(O)ONHR3-csoport, amiben R1jelentése 1-4 szénatomszámos alkilcsoport, fenil-(1-4 szénatomszámosalkilenil)-, vagy heteroaril-(1-4 szénatomszámos alkilenil)-csoport;R2 jelentése hidrogénatom vagy 1-4 szénatomszámos alkilcsoport; R3jelentése 1-4-szénatomszámos alkilcsoport, egy heterociklusos- vagyfenilcsoport, adott esetben halogénatommal vagy hidroxicsoporttalhelyettesítve; valamint ezek gyógyászatilag elfogadható savaddícióssói és szolvátjai, azzal a feltétellel, hogy ha A-B jelentése -C=CH-,akkor X nem lehet hidroxicsoport, halogénatom vagy 1-4-szénatomosalkoxicsoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/970,637 US5905084A (en) | 1997-11-14 | 1997-11-14 | 5-HTIF -agonists effective in treating migraine |
| PCT/US1998/024256 WO1999025348A1 (en) | 1997-11-14 | 1998-11-13 | 5-ht1f agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0004317A2 true HUP0004317A2 (hu) | 2001-10-28 |
| HUP0004317A3 HUP0004317A3 (en) | 2002-03-28 |
Family
ID=25517243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004317A HUP0004317A3 (en) | 1997-11-14 | 1998-11-13 | 5-ht1f agonists |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5905084A (hu) |
| EP (1) | EP0916670B1 (hu) |
| JP (1) | JP2001522887A (hu) |
| KR (1) | KR20010032085A (hu) |
| CN (1) | CN1284874A (hu) |
| AT (1) | ATE240326T1 (hu) |
| AU (1) | AU1407299A (hu) |
| BR (1) | BR9814188A (hu) |
| CA (1) | CA2310248A1 (hu) |
| DE (1) | DE69814563T2 (hu) |
| DK (1) | DK0916670T3 (hu) |
| EA (1) | EA200000522A1 (hu) |
| ES (1) | ES2198657T3 (hu) |
| HR (1) | HRP20000297A2 (hu) |
| HU (1) | HUP0004317A3 (hu) |
| ID (1) | ID25478A (hu) |
| IL (1) | IL135634A0 (hu) |
| NO (1) | NO20002408L (hu) |
| PL (1) | PL340459A1 (hu) |
| PT (1) | PT916670E (hu) |
| TR (1) | TR200001724T2 (hu) |
| WO (1) | WO1999025348A1 (hu) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001012629A1 (en) * | 1999-08-12 | 2001-02-22 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
| WO2001029263A1 (en) * | 1999-10-19 | 2001-04-26 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the 5-hydroxytryptamine (serotonin) receptor 1e gene |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| JP2006523692A (ja) | 2003-04-18 | 2006-10-19 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物 |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| DE602004008338T2 (de) | 2003-12-17 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten |
| US8030344B2 (en) * | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2011123654A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
| TWI776175B (zh) | 2019-07-09 | 2022-09-01 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007926A1 (en) * | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| CZ288897A3 (cs) * | 1995-03-20 | 1998-02-18 | Eli Lilly And Company | V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje |
| AU7261196A (en) * | 1995-10-10 | 1997-04-30 | Eli Lilly And Company | N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists |
| ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
-
1997
- 1997-11-14 US US08/970,637 patent/US5905084A/en not_active Expired - Fee Related
-
1998
- 1998-11-13 WO PCT/US1998/024256 patent/WO1999025348A1/en not_active Application Discontinuation
- 1998-11-13 AT AT98309321T patent/ATE240326T1/de not_active IP Right Cessation
- 1998-11-13 ID IDW20000837A patent/ID25478A/id unknown
- 1998-11-13 ES ES98309321T patent/ES2198657T3/es not_active Expired - Lifetime
- 1998-11-13 IL IL13563498A patent/IL135634A0/xx unknown
- 1998-11-13 DE DE69814563T patent/DE69814563T2/de not_active Expired - Fee Related
- 1998-11-13 TR TR2000/01724T patent/TR200001724T2/xx unknown
- 1998-11-13 EP EP98309321A patent/EP0916670B1/en not_active Expired - Lifetime
- 1998-11-13 EA EA200000522A patent/EA200000522A1/ru unknown
- 1998-11-13 JP JP2000520781A patent/JP2001522887A/ja not_active Withdrawn
- 1998-11-13 AU AU14072/99A patent/AU1407299A/en not_active Abandoned
- 1998-11-13 HU HU0004317A patent/HUP0004317A3/hu unknown
- 1998-11-13 DK DK98309321T patent/DK0916670T3/da active
- 1998-11-13 KR KR1020007005209A patent/KR20010032085A/ko not_active Application Discontinuation
- 1998-11-13 CA CA002310248A patent/CA2310248A1/en not_active Abandoned
- 1998-11-13 CN CN98812914A patent/CN1284874A/zh active Pending
- 1998-11-13 PT PT98309321T patent/PT916670E/pt unknown
- 1998-11-13 PL PL98340459A patent/PL340459A1/xx unknown
- 1998-11-13 BR BR9814188-0A patent/BR9814188A/pt not_active Application Discontinuation
-
2000
- 2000-05-09 NO NO20002408A patent/NO20002408L/no not_active Application Discontinuation
- 2000-05-12 HR HR20000297A patent/HRP20000297A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US5905084A (en) | 1999-05-18 |
| HRP20000297A2 (en) | 2000-12-31 |
| ATE240326T1 (de) | 2003-05-15 |
| DK0916670T3 (da) | 2003-09-15 |
| DE69814563D1 (de) | 2003-06-18 |
| EP0916670A3 (en) | 2001-05-23 |
| EP0916670A2 (en) | 1999-05-19 |
| DE69814563T2 (de) | 2004-04-08 |
| JP2001522887A (ja) | 2001-11-20 |
| KR20010032085A (ko) | 2001-04-16 |
| CN1284874A (zh) | 2001-02-21 |
| CA2310248A1 (en) | 1999-05-27 |
| EA200000522A1 (ru) | 2000-10-30 |
| PL340459A1 (en) | 2001-02-12 |
| BR9814188A (pt) | 2000-10-03 |
| WO1999025348A1 (en) | 1999-05-27 |
| NO20002408L (no) | 2000-07-12 |
| TR200001724T2 (tr) | 2000-11-21 |
| PT916670E (pt) | 2003-09-30 |
| EP0916670B1 (en) | 2003-05-14 |
| IL135634A0 (en) | 2001-05-20 |
| NO20002408D0 (no) | 2000-05-09 |
| ID25478A (id) | 2000-10-05 |
| AU1407299A (en) | 1999-06-07 |
| HUP0004317A3 (en) | 2002-03-28 |
| ES2198657T3 (es) | 2004-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0105142A2 (hu) | 4-oxo-1,4-dihidro-3-kinolin-karboxamid-származékok, mint vírusellenes hatóanyagok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0300909A2 (hu) | NHE-3 inhibitor hatású 2-guanidino-4-aril-kinazolin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DK129282A (da) | Fremgangsmaade til fremstilling af indolylethylderivater | |
| DE3876813D1 (de) | 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a. | |
| HUP9902993A2 (hu) | Alkil-amino-benztiazol és -benzoxazol-származékok | |
| HUP0004317A2 (hu) | 5-HT1F agonisták | |
| AU2636988A (en) | New 2-(piperazinyl)-2-substituted flavonoid derivatives, processes for preparing them and pharmaceutical compositions containing them | |
| ES448175A1 (es) | Procedimiento para la preparacion de propargil-2-fenilamino-imidazolinas-(2). | |
| IE45556L (en) | 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives | |
| HUP0004055A2 (hu) | Aminoetil-fenoxi-ecetsav-származékok vesekő okozta fájdalom csillapítására és vesekő eltávolítás elősegítésére | |
| HUP0303457A2 (hu) | Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk | |
| DE60000978D1 (de) | 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose | |
| HUP9900642A2 (hu) | Símaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
| AU584225B2 (en) | Steroidic aromatase inhibitors | |
| DE60004669D1 (de) | Indolocarbazolalkaloide aus einer marinen actinomycete | |
| HUP9901030A2 (hu) | Helyettesített N-metil-N-(4-(4-(1H-benzimidazol-2-il)-amino)-piperidin-1-il)-2-(aril)-butil)-benzamid-származékok, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| HUP0104244A2 (hu) | Növekedési hormon elválasztását serkentő vegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| NZ223664A (en) | 2,3-dihydro-3-phenyl-2-oxo-benzofuranylacetic acid amide derivatives and pharmaceutical compositions | |
| DK1027055T3 (da) | 3-Carboalkoxy-2,3-dihydro-1H-phenothiazin-4(10H)-on-derivater | |
| ES8607944A1 (es) | Procedimiento para la preparacion de nuevos derivados de 1- fenilimidazolidin-2-ona | |
| HUP0402229A2 (hu) | TNF-aktivitású tetrahidropiridil-alkil-heterociklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0001942A2 (hu) | 4-Amino-alkoxi-1,3-dihidro-benzimidazol-2-tion-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| AU561149B2 (en) | Cardiotonic 4-semicarbazide quindyolines |